Stock 002349 JINGHUA PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jinghua Pharmaceutical Group Co., Ltd.

Equities

002349

CNE100000L14

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 09/05/2024 BST 		5-day change 1st Jan Change
7.97 CNY -1.97% Intraday chart for Jinghua Pharmaceutical Group Co., Ltd. +1.14% -10.15%
04-29 Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-18 Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 4,789 3,648 3,989 9,184 9,835 7,222
Enterprise Value (EV) 1 4,991 3,822 3,590 8,514 8,800 6,005
P/E ratio 20.8 x -9.27 x 36 x 57.1 x 46.3 x 29.2 x
Yield 0.87% - 0.84% 0.53% 0.66% -
Capitalization / Revenue 3.53 x 3.15 x 3.11 x 6.76 x 6.25 x 4.78 x
EV / Revenue 3.68 x 3.3 x 2.8 x 6.27 x 5.59 x 3.97 x
EV / EBITDA 13.6 x -90.8 x 12.1 x 33.1 x 27.7 x 15.2 x
EV / FCF -79.3 x -131 x 16.4 x 122 x 44.3 x 42.3 x
FCF Yield -1.26% -0.76% 6.09% 0.82% 2.26% 2.37%
Price to Book 2.04 x 1.97 x 1.89 x 4.11 x 4.1 x 2.95 x
Nbr of stocks (in thousands) 835,724 814,181 814,181 814,181 814,181 814,181
Reference price 2 5.730 4.480 4.900 11.28 12.08 8.870
Announcement Date 17/02/19 28/04/20 26/04/21 29/03/22 29/03/23 18/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,355 1,157 1,281 1,358 1,573 1,512
EBITDA 1 367.4 -42.08 295.8 257.4 318 394.9
EBIT 1 289.4 -122.4 213.7 156.5 211.4 310.7
Operating Margin 21.37% -10.58% 16.68% 11.53% 13.44% 20.55%
Earnings before Tax (EBT) 1 288.5 -500.7 63.74 178.9 250.2 329.7
Net income 1 229.7 -393.6 111 160.7 212.2 247.7
Net margin 16.95% -34.01% 8.66% 11.83% 13.49% 16.38%
EPS 2 0.2756 -0.4835 0.1363 0.1974 0.2607 0.3042
Free Cash Flow 1 -62.95 -29.22 218.8 69.94 198.7 142.1
FCF margin -4.65% -2.53% 17.07% 5.15% 12.63% 9.4%
FCF Conversion (EBITDA) - - 73.96% 27.17% 62.49% 35.98%
FCF Conversion (Net income) - - 197.1% 43.52% 93.64% 57.37%
Dividend per Share 2 0.0500 - 0.0410 0.0600 0.0800 -
Announcement Date 17/02/19 28/04/20 26/04/21 29/03/22 29/03/23 18/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 203 174 - - - -
Net Cash position 1 - - 399 670 1,036 1,217
Leverage (Debt/EBITDA) 0.5513 x -4.138 x - - - -
Free Cash Flow 1 -63 -29.2 219 69.9 199 142
ROE (net income / shareholders' equity) 9.74% -21.7% 1.21% 5.54% 8.18% 10.2%
ROA (Net income/ Total Assets) 5.45% -2.41% 4.38% 3.08% 4.23% 6.24%
Assets 1 4,216 16,313 2,533 5,220 5,012 3,971
Book Value Per Share 2 2.800 2.270 2.590 2.750 2.950 3.000
Cash Flow per Share 2 0.2600 0.3700 0.7100 0.8000 1.150 1.130
Capex 1 160 255 118 80.5 61.6 28.4
Capex / Sales 11.83% 22.06% 9.25% 5.93% 3.92% 1.88%
Announcement Date 17/02/19 28/04/20 26/04/21 29/03/22 29/03/23 18/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
JINGHUA PHARMACEUTICAL GROUP CO., LTD. Stock Jinghua Pharmaceutical Group Co., Ltd.
-10.15% 898M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002349 Stock
  4. Financials Jinghua Pharmaceutical Group Co., Ltd.